Scope and Claims Analysis for US Patent 6,063,771 (Pediculicidal Spinosyn Shampoos): What’s Covered, What’s Not, and How Competitive Entry Risks Map to Claim Boundaries

US Patent 6,063,771 is a formulation-and-method patent focused on pediculicidal shampoos and hair treatment methods that use a spinosyn (or a specified tetracyclic N-demethyl derivative or salt) in combination with tightly defined concentrations of specific surfactants, amides, and optional non-volatile silicones and suspending agents. The practical scope is claim-driven: the patent is strongest where accused products match the spinosyn identity/category and the quantitative formulation windows, and weakest where an accused product substitutes key functional components (especially outside the claim concentration ranges) or uses a different active class.

What does US 6,063,771 claim for pediculicidal shampoo scope and coverage?

Core independent claim (Claim 1): formulation window architecture

Claim 1 is the primary infringement anchor. It recites a shampoo comprising:

Active (spinosyn / tetracyclic N-demethyl derivative or salt):

0.1% to 30%

Synthetic surfactant:

5% to 30%

Amide:

1% to 7%
(amide identity is narrowed in dependent claims)

Water:

implicit carrier component; no concentration stated beyond being a shampoo.

Scope implication: Claim 1 is broad on the identity of the “synthetic surfactant” (any anionic/amphoteric/cationic/zwitterionic/non-ionic category is later confirmed in Claim 2) and broad on the “amide” category (later narrowed). It is narrow on the numerical ranges, which become the main claim-limiting features in validity and infringement analyses.

Claim 2 (surfactant class broadening)

Claim 2 specifies the synthetic surfactant can be any of:

anionic, amphoteric, cationic, zwitterionic, or non-ionic, or mixtures.

Scope implication: This claim removes design-around pressure based on surfactant charge type. If the formulation uses “a synthetic surfactant” within the Claim 1 % window, switching ionic class does not avoid Claim 2.

Claim 3 (amide identity narrowing)

Claim 3 limits the amide to:

coconut monoethanolamide or coconut diethanolamide, or mixtures.

Scope implication: If an accused product uses a different amide (e.g., oleamide, isopropanolamide, behenamide, synthetic fatty amides not coconut-derived), it can potentially fall outside Claim 3. But Claim 1 may still be implicated if the different amide still falls within the undefined “amide” category used in Claim 1 (depending on how “amide” is interpreted during claim construction and whether coconut-specific limitation is required by the asserted claim set).

Claims 4–8 (optional silicone, then suspending agent system)

These are dependent add-ons that expand coverage only if the product includes the specified features.

Claim 4: additionally comprises 1% to 10% non-volatile silicone material
Claim 5: non-volatile silicone must be selected from:
- polyalkyl siloxane
- polyalkylaryl siloxane
- polyether siloxane co-polymer
  with viscosity 100 cP to 150,000,000 cP at 25°C
Claim 6: additionally comprises 0.5% to 5% suspending agent selected from:
- crystalline amphiphilic materials with needle-like or platelet structures
- polymeric materials
- clays
- fumed metal oxides or mixtures
Claim 7: crystalline amphiphilic materials are selected from:
- long chain C16–C22 acyl derivatives
- long chain C16–C22 alkanolamides of fatty acids or mixtures
Claim 8: crystalline amphiphilic material is ethylene glycol diester

Scope implication: Claims 4–8 function like a ladder. A product can infringe Claim 1 without infringing Claims 4–8 if it lacks non-volatile silicone or uses different silicone/suspending agent. But once a product includes non-volatile silicone and the viscosity window, and also includes a crystalline amphiphilic suspending agent with needle/platelet morphology (or the ethylene glycol diester form per Claim 8), the formulation fit becomes very specific.

Claim 9 (tight spinosyn concentration sub-window)

Claim 9 narrows spinosyn/tetracyclic derivative content to:

0.25% to 1.5%

Scope implication: Claim 9 is narrower than Claim 1. It is typically asserted where the accused product uses a low-to-mid spinosyn level closer to commercial insecticidal shampoos.

What do the method claims in US 6,063,771 cover for lice treatment and egg removal?

Method for controlling lice infestation (Claims 10–13)

Claim 10: method for controlling a lice infestation in a human by topically administering an effective amount of the claimed spinosyn/tetracyclic derivative formulation.
Claim 11: lice infestation is Pediculus humanus capitis (head lice)
Claim 12: Pediculus humanus humanus (body lice)
Claim 13: Pthirus pubis (pubic lice)

Scope implication: These claims are not limited to shampoo leave-time or gram dosing unless tied to Claim 14’s procedure. They can be infringed by topical use of a matching formulation, with species identity being the main qualifier (head/body/pubic).

Method for treating human hair (Claim 14): process-specific performance window

Claim 14 recites:

a) apply 10 g to 30 g of a formulation comprising:

spinosyn (or tetracyclic N-demethyl derivative or salt)
physiologically acceptable carrier
to wet hair

b) work through hair and scalp
c) leave on 6 to 10 minutes
d) remove by rinsing with water

Scope implication: Claim 14 is operationally specific. If an accused label instructs a different gram range, different leave-time, or a different product form (non-shampoo), Claim 14 may be avoided even if Claim 1 is still implicated.

Where are the claim boundaries for infringement risk: concentration windows, ingredient identity, and optional add-ons?

1) Spinosyn category and “tetracyclic N-demethyl derivative or salt”

The patent is not restricted to a single spinosyn molecule in the text you provided; it covers:

“a spinosyn” or
a “physiologically acceptable tetracyclic N-demethyl derivative or salt.”

Practical risk: If a competitor uses a spinosyn active ingredient or a covered tetracyclic N-demethyl derivative/salt, the active element is likely to remain within scope. If the competitor uses a different pediculicide class (e.g., pyrethroids, organophosphates, ivermectin-like agents, dimethicone-only approaches, etc.), the claims are structurally harder to reach.

2) Synthetic surfactant: category is broad, concentration is not

Surfactant must be “synthetic” and 5% to 30%.
Charge type does not matter given Claim 2.

Design-around pressure point: Use surfactant below 5% or reduce synthetic surfactant concentration by shifting to non-synthetic surfactants or different carrier systems may reduce Claim 1 fit. But “synthetic surfactant” wording can be litigated depending on ingredient sourcing and definitions in claim construction.

3) Amide: coconut mono/diethanolamides are claim 3 specific

Claim 1 requires “an amide” 1% to 7%
Claim 3 specifies coconut monoethanolamide/diethanolamide.

Risk mapping:

If an accused shampoo uses coconut mono/diethanolamide in the 1%–7% window, it aligns with Claims 3 and 1.
If it uses different amides, Claim 3 may be avoided but Claim 1’s “amide” category still requires careful claim construction.

4) Silicone: only covered when non-volatile and within defined polymer classes and viscosity

Non-volatile silicone 1% to 10%
Must be from defined silicone polymer types
Must meet a viscosity range 100 cP to 150,000,000 cP at 25°C

Design-around pressure point: Avoid non-volatile silicone, use silicone outside the defined polymer classes, or fall outside viscosity window.

5) Suspensions and crystalline amphiphilic morphology: narrow dependent coverage

Suspending agent 0.5% to 5%
Includes crystalline amphiphilic materials with needle-like or platelet structures

Then Claim 7 narrows crystalline amphiphilic materials to long chain C16–C22 acyl derivatives or long chain C16–C22 alkanolamides.

Then Claim 8 narrows one embodiment to ethylene glycol diester.

Risk mapping:

A formulation without suspending agent or with different suspension mechanics may avoid dependent claims 6–8.
A formulation with an ethylene glycol diester crystalline amphiphile is high-risk for Claim 8 alignment.

6) Operational method claims: grams and minutes

Claim 14: 10–30 g, leave 6–10 min
Species is addressed earlier in Claims 11–13.

Design-around pressure point: Label instructions outside the claimed leave-time or application quantity reduce Claim 14 reach, though they may not prevent Claim 10–13 if formulation administration still meets Claim 10.

How strong is the patent estate for US 6,063,771 based on claim drafting features?

Strength drivers

Numerical concentration windows create a measurable infringement test for Claim 1.
Multiple dependent claims layer additional formulation features (surfactant type, coconut amides, silicone, suspending agents).
Method claims add additional infringement pathways even if product form differs slightly, provided topical administration of the claimed formulation occurs.

Potential vulnerability drivers (from claim perspective)

Breadth of “spinosyn” / derivative category can create prior-art overlap issues in validity challenges if earlier disclosures contain similar actives and insecticidal shampoo compositions.
Claims 4–8 depend on optional components; if a competitor uses a different vehicle system, infringement may narrow to Claim 1/2/3 and method claims 10–13.
Claim 14 is specific to application logistics; competitors can sometimes shift instructions (or product format) to reduce risk.

What patent landscape questions matter most for competitors: what patents protect, what patents block, and where are generic entry risks?

Without integrating a full Orange Book or patent-citation dataset, the most actionable landscape conclusion from the claim text alone is this:

Entry risk is highest where a competitor’s pediculicidal shampoo:
- uses a spinosyn or covered tetracyclic N-demethyl derivative/salt
- lands within 0.1%–30% spinosyn
- uses a synthetic surfactant at 5%–30%
- uses an amide (or coconut mono/diethanolamide if Claim 3 is asserted) at 1%–7%
- optionally includes the silicone and suspending agent systems aligned to Claims 4–8
- includes labeled use consistent with Claim 14’s 10–30 g and 6–10 minute leave-time (for method claim exposure).
Entry risk is reduced where a product:
- uses a non-spinosyn active class,
- uses a shampoo vehicle without the required concentration of synthetic surfactant or amide,
- avoids non-volatile silicone in the specified polymer classes/viscosity window, or
- uses different application protocol than Claim 14.

How do the dependent formulation claims expand coverage compared with Claim 1?

Claim coverage matrix (ingredient and parameter alignment)

Claim	Required active	Synthetic surfactant	Amide	Non-volatile silicone	Suspending agent	Operational constraints
1	spinosyn or tetracyclic N-demethyl derivative/salt	5%–30%	1%–7%	Not required	Not required	Shampoo formulation only
2	same as 1	5%–30% (same)	1%–7%	Not required	Not required	Surfactant can be any listed class
3	same as 1	5%–30%	coconut mono/diethanolamide 1%–7%	Not required	Not required	Amide identity limitation
4	same as 1	5%–30%	1%–7%	1%–10% required	Not required	Adds silicone layer
5	same as 1	5%–30%	1%–7%	1%–10% non-volatile, specific polymers, viscosity 100 cP–150,000,000 cP	Not required	Adds silicone chemistry/viscosity limitation
6	same as 1	5%–30%	1%–7%	as in 5	0.5%–5% suspending agent (broad list)	Adds suspending agent
7	same as 1	5%–30%	1%–7%	as in 5	suspending agent crystalline amphiphile C16–C22 acyl/alkanolamide	Narrows suspending agent chemistry
8	same as 1	5%–30%	1%–7%	as in 5	suspending agent is ethylene glycol diester	Narrows to a single embodiment
9	same as 1	5%–30%	1%–7%	not required	not required	spinosyn 0.25%–1.5%
10	same as 1	Not limited (topical admin of formulation)	Not limited	Not limited	Not limited	“Effective amount” of formulation
11–13	same as 10	same	same	same	same	Specific lice species
14	same as 1	not quantified (by method steps)	not quantified	not quantified	not quantified	10–30 g; wet hair; leave 6–10 min; rinse

Which formulation changes are most likely to move a competitor outside these claims?

High-leverage design changes

Switch away from spinosyn/tetracyclic N-demethyl derivative/salt
This attacks the active element and is the cleanest path out of all claims 1–9 and 10–14.
Reduce synthetic surfactant below 5% or above 30%
This can avoid Claim 1 and Claim 2 if “synthetic surfactant” is characterized that way.
Change amide chemistry away from coconut mono/diethanolamides (Claim 3)
This may avoid Claim 3 specifically. It may or may not avoid Claim 1 depending on whether “amide” in Claim 1 is argued broadly.
Remove non-volatile silicone in the specified classes (Claims 4–8)
Avoiding silicone or using different silicone chemistry/viscosity can reduce dependent claim exposure.
Avoid crystalline amphiphilic needle/platelet suspending agents or ethylene glycol diester (Claims 6–8)
This can narrow dependent claim risk.
Shift dosing instructions and leave time away from 10–30 g and 6–10 minutes (Claim 14)
This may reduce method claim exposure while leaving product infringement exposure still possible.

Key Takeaways

US 6,063,771 is anchored by a concentration-defined shampoo formulation (Claim 1) using a spinosyn or tetracyclic N-demethyl derivative/salt plus synthetic surfactant (5%–30%) and amide (1%–7%).
Dependent claims expand risk when products include non-volatile silicone (Claims 4–5), suspending agents with crystalline amphiphilic morphology (Claims 6–8), and specific coconut mono/diethanolamide (Claim 3).
Method claims (Claims 10–13) cover topical administration for specific lice species; Claim 14 adds process constraints (10–30 g, leave 6–10 minutes, rinse).
Competitive entry risk is highest when a competitor product matches not only the active category but also the surfactant and amide windows and, if used, the silicone and crystalline suspending agent systems plus the leave-time protocol.

FAQs

How do I evaluate whether a competitor “surfactant” meets the “synthetic surfactant” limitation in Claim 1?
Focus on ingredient classification as synthetic and confirm surfactant concentration falls within 5%–30%.
Can a product avoid Claim 3 (coconut mono/diethanolamides) while still infringing Claim 1?
Yes, potentially. Claim 3 is amide identity-specific; Claim 1 still requires only “an amide” at 1%–7%, subject to claim construction of “amide.”
What is the most important numerical range for infringement of the core formulation claim?
The synthetic surfactant 5%–30% and amide 1%–7% ranges, combined with the spinosyn category being within 0.1%–30%.
Does using different lice-control instructions avoid only Claim 14 or also Claims 10–13?
Avoiding Claim 14 depends on matching the 10–30 g and 6–10 minute instructions. Claims 10–13 focus on topical administration of the formulation for specific lice species and are not tied to leave-time.
If a competitor removes non-volatile silicone, what claims remain at risk?
Claims that do not require silicone: 1–3, and method claims 10–13 (and potentially 14 if process steps match).

References (APA)

United States Patent 6,063,771.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	326212	⤷ Start Trial
Australia	4700499	⤷ Start Trial
Australia	750046	⤷ Start Trial
Brazil	9911795	⤷ Start Trial
Canada	2337789	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,063,771

Summary for Patent: 6,063,771